市場調查報告書
商品編碼
1028283

中國的Dabigatran Etexilate 市場(2021年∼2025年)

Research Report on China's Dabigatran Etexilate Market, 2021-2025

出版日期: | 出版商: China Research and Intelligence | 英文 40 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

中國的Dabigatran Etexilate 的銷售額,由於COVID-19的影響,2020年約減少到3億2,900萬元(5,060萬美元)。中國的Dabigatran Etexilate 市場,2020年以前由Boehringer Ingelheim International GmbH完全獨佔。2020年儘管Chia Tai Tianqing的Dabigatran Etexilate 發售,Boehringer Ingelheim International GmbH,在中國市場維持著99%以上的銷售量佔有率。但,中國市場中Boehringer Ingelheim International GmbH的佔有率,隨著學名藥增加降低。

本報告提供中國的Dabigatran Etexilate 市場的相關調查,市場規模和預測,市場動態,COVID-19的影響,開發環境,主要製造商及市場佔有率,銷售價格等資訊。

目錄

第1章 Dabigatran Etexilate 的相關概念

  • Dabigatran Etexilate 的適應症
  • 中國的Dabigatran Etexilate 市場發展
  • 中國的Dabigatran Etexilate 的政府核准
  • COVID-19對中國的Dabigatran Etexilate 市場的影響

第2章 中國的Dabigatran Etexilate 銷售(2016-2020)

  • 銷售額
    • 中國的銷售額
    • 各地區:中國的銷售額
  • 銷售量
    • 中國的銷售量
    • 各地區:中國的銷售量
  • 各劑型:中國的Dabigatran Etexilate 銷售(2016-2020)
    • 膠囊
    • 其他

第3章 中國的主要Dabigatran Etexilate 製造商分析(2020)

  • 市場佔有率分析
    • 各銷售額製造商市場佔有率
    • 各銷售量製造商市場佔有率
  • Boehringer Ingelheim International GmbH
    • 企業簡介
    • 中國的Dabigatran Etexilate 銷售
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    • 企業簡介
    • 中國的Dabigatran Etexilate 銷售

第4章 各企業的中國的Dabigatran Etexilate 銷售價格(2020-2021)

  • Boehringer Ingelheim International GmbH (Pradaxa (R))
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Anershun (R))

第5章 中國的Dabigatran Etexilate 市場預測(2021-2025)

  • 市場開發的影響因素
    • COVID-19對市場的影響
    • 市場成長要素和機會
    • 市場威脅與課題
  • 市場規模的預測
  • 市場趨勢的預測
目錄
Product Code: 2109557

Dabigatran Etexilate is an oral anticoagulant drug used for the prevention of thrombus and embolus formation after major orthopedic surgery (hip or knee replacement) and for the prevention of stroke in people with non-valvular atrial fibrillation and other embolisms of the body circulation.

Dabigatran etexilate is a precursor drug of dabigatran that is enzymatically hydrolyzed in vivo to the coagulant-active dabigatran, which exerts its anticoagulant effect through direct inhibition of thrombin. Dabigatran etexilate mesylate capsules, originally developed by Boehringer Ingelheim under the trade name of Pradaxa®, were approved for marketing by EMA in March 2008 and then approved by FDA in 2010. After the launch, its sales value peaked at USD1.60 billion in 2013. The sales value then started to decrease due to the launch of other competitive anticoagulants like rivaroxaban and apixaban.

In March 2013, Dabigatran etexilate capsules were approved in China for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation, under the trade name of Taibiquan® with the specifications of 110 mg/capsule and 150 mg/capsule. In 2017, Dabigatran etexilate immediate-release formulation for oral use has been included in the Category B drugs in the latest China National Reimbursement Drug List. In March 2020, Chia Tai Tianqing's generic dabigatran etexilate capsules were approved by the NMPA for marketing in China, followed by Jiangsu Hansoh Pharmaceutical and Chengdu Easton Bio Pharmaceuticals in early 2021. And It is expected that, from 2021 to 2025, more generic dabigatran etexilate drugs will be approved.

According to CRI's market research, the sales value of dabigatran etexilate in China declined to approximately CNY329 million (USD50.6 million) in 2020 due to COVID-19. And China's dabigatran etexilate market was entirely dominated by Boehringer Ingelheim International GmbH before 2020. Despite the launch of Chia Tai Tianqing's dabigatran etexilate in 2020, Boehringer Ingelheim International GmbH still held more than 99% share of the dabigatran etexilate market in China in terms of sales value. It is expected that Boehringer Ingelheim International GmbH's share of China's dabigatran etexilate market will decline for more generic products will become available.

Topics Covered:

Impact of COVID-19 on China's Dabigatran Etexilate Market

Development Environment of Dabigatran Etexilate in China

Sales Volume of Dabigatran Etexilate in China

Sales Volume and Value of Dabigatran Etexilate in China by Region

Major Dabigatran Etexilate Manufacturers in China and Their Market Shares

Sales Price of Dabigatran Etexilate in China

Prospects of China's Dabigatran Etexilate Market, 2021-2025

Table of Contents

1 Relevant Concept of Dabigatran Etexilate

  • 1.1 Indications of Dabigatran Etexilate
  • 1.2 Development of China's Dabigatran Etexilate Market
  • 1.3 Governmental Approval of Dabigatran Etexilate in China
  • 1.4 The Impact of COVID-19 on China's Dabigatran Etexilate Market

2 Sales of Dabigatran Etexilate in China, 2016-2020

  • 2.1 Sales Value
    • 2.1.1 Sales Value in China
    • 2.1.2 Sales Value in China by Region
  • 2.2 Sales Volume
    • 2.2.1 Sales Volume in China
    • 2.2.2 Sales Volume in China by Region
  • 2.3 Sales of Dabigatran Etexilate in China by Dosage Form, 2016-2020
    • 2.3.1 Capsules
    • 2.3.2 Other Dosage Forms

3 Analysis of Major Dabigatran Etexilate Manufacturers in China, 2020

  • 3.1 Analysis of Market Share
    • 3.1.1 Market Share of Manufacturers by Sales Value
    • 3.1.2 Market Share of Manufacturers by Sales Volume
  • 3.2 Boehringer Ingelheim International GmbH
    • 3.2.1 Company Profile
    • 3.2.2 Sales of Dabigatran Etexilate in China
  • 3.3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    • 3.3.1 Company Profile
    • 3.3.2 Sales of Dabigatran Etexilate in China

4 Sales Price of Dabigatran Etexilate of Different Companies in China, 2020-2021

  • 4.1 Boehringer Ingelheim International GmbH (Pradaxa®)
  • 4.2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Anershun®)

5 Prospects of China's Dabigatran Etexilate Market, 2021-2025

  • 5.1 Influencing Factors for the Market Development
    • 5.1.1 The Impact of COVID-19 on the Market
    • 5.1.2 Market Drivers and Opportunities
    • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

List of Charts

  • Chart Patent Information of Dabigatran Etexilate in China
  • Chart Sales Value of Dabigatran Etexilate in China, 2016-2020
  • Chart Sales Volume of Dabigatran Etexilate in China, 2016-2020
  • Chart Sales of Dabigatran Etexilate Tablets in China, 2016-2020
  • Chart Sales Volume of Dabigatran Etexilate in China by Region, 2016-2020
  • Chart Sales Value of Dabigatran Etexilate in China by Region, 2016-2020
  • Chart Market Share of Dabigatran Etexilate Manufacturers in China by Sales Value, 2016-2020
  • Chart Sales Value and Volume of Dabigatran Etexilate (of Boehringer Ingelheim International GmbH) in China, 2016-2020
  • Chart Sales Value and Volume of Dabigatran Etexilate (of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.) in China, 2016-2020
  • Chart Sales Price of Pradaxa (Dabigatran Etexilate of Boehringer Ingelheim International GmbH) in China by Region, 2020
  • Chart Sales Price of Anershun (Dabigatran Etexilate of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.) in China by Region, 2020
  • Chart Forecast on Sales Value of Dabigatran Etexilate in China, 2021-2025
  • Chart Forecast on Sales Volume of Dabigatran Etexilate in China, 2021-2025